1
|
Córdova LA, Trichet V, Escriou V, Rosset P, Amiaud J, Battaglia S, Charrier C, Berreur M, Brion R, Gouin F, Layrolle P, Passuti N, Heymann D. Inhibition of osteolysis and increase of bone formation after local administration of siRNA-targeting RANK in a polyethylene particle-induced osteolysis model. Acta Biomater 2015; 13:150-8. [PMID: 25462844 DOI: 10.1016/j.actbio.2014.10.042] [Citation(s) in RCA: 32] [Impact Index Per Article: 3.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/05/2014] [Revised: 10/25/2014] [Accepted: 10/28/2014] [Indexed: 01/24/2023]
Abstract
Receptor activator of nuclear factor kappa-B (RANK) and RANK-ligand are relevant targets for the treatment of polyethylene particle-induced osteolysis. This study assessed the local administration of siRNA, targeting both human RANK and mouse Rank transcripts in a mouse model. Four groups of mice were implanted with polyethylene (PE) particles in the calvaria and treated locally with 2.5, 5 and 10 μg of RANK siRNA or a control siRNA delivered by the cationic liposome DMAPAP/DOPE. The tissues were harvested at day 9 after surgery and evaluated by micro-computed tomography, tartrate-resistant acid phosphatase (TRAP) immunohistochemistry for macrophages and osteoblasts, and gene relative expression of inflammatory and osteolytic markers. 10 μg of RANK siRNA exerted a protective effect against PE particle-induced osteolysis, decreasing the bone loss and the osteoclastogenesis, demonstrated by the significant increase in the bone volume (P<0.001) and by the reduction in both the number of TRAP(+) cells and osteoclast activity (P<0.01). A bone anabolic effect demonstrated by the formation of new trabecular bone was confirmed by the increased immunopositive staining for osteoblast-specific proteins. In addition, 5 and 10 μg of RANK siRNA downregulated the expression of pro-inflammatory cytokines (P<0.01) without depletion of macrophages. Our findings show that RANK siRNA delivered locally by a synthetic vector may be an effective approach for reducing osteolysis and may even stimulate bone formation in aseptic loosening of prosthetic implants.
Collapse
Affiliation(s)
- L A Córdova
- INSERM, UMR 957, 1 rue Gaston Veil, 44035 Nantes Cedex 1, France; University of Nantes, Nantes Atlantique Universities, Laboratory of Pathophysiology of Bone Resorption and Therapy of Primary Bone Tumours, 1 rue Gaston Veil, 44035 Nantes Cedex 1, France; Department of Oral and Maxillofacial Surgery, San Borja Arriaran University Hospital, Faculty of Dentistry, University of Chile-CONICYT, Sergio Livingstone Polhammer 943, Independencia, Santiago, Chile.
| | - V Trichet
- INSERM, UMR 957, 1 rue Gaston Veil, 44035 Nantes Cedex 1, France; University of Nantes, Nantes Atlantique Universities, Laboratory of Pathophysiology of Bone Resorption and Therapy of Primary Bone Tumours, 1 rue Gaston Veil, 44035 Nantes Cedex 1, France
| | - V Escriou
- UTCBS CNRS UMR 8258 INSERM UMR-S 1022, 4 avenue de l'Observatoire, 75006 Paris, France
| | - P Rosset
- INSERM, UMR 957, 1 rue Gaston Veil, 44035 Nantes Cedex 1, France; University of Nantes, Nantes Atlantique Universities, Laboratory of Pathophysiology of Bone Resorption and Therapy of Primary Bone Tumours, 1 rue Gaston Veil, 44035 Nantes Cedex 1, France; Tours University Hospital, François Rabelais, 37044 Tours Cedex 9, France
| | - J Amiaud
- INSERM, UMR 957, 1 rue Gaston Veil, 44035 Nantes Cedex 1, France; University of Nantes, Nantes Atlantique Universities, Laboratory of Pathophysiology of Bone Resorption and Therapy of Primary Bone Tumours, 1 rue Gaston Veil, 44035 Nantes Cedex 1, France
| | - S Battaglia
- INSERM, UMR 957, 1 rue Gaston Veil, 44035 Nantes Cedex 1, France; University of Nantes, Nantes Atlantique Universities, Laboratory of Pathophysiology of Bone Resorption and Therapy of Primary Bone Tumours, 1 rue Gaston Veil, 44035 Nantes Cedex 1, France
| | - C Charrier
- INSERM, UMR 957, 1 rue Gaston Veil, 44035 Nantes Cedex 1, France; University of Nantes, Nantes Atlantique Universities, Laboratory of Pathophysiology of Bone Resorption and Therapy of Primary Bone Tumours, 1 rue Gaston Veil, 44035 Nantes Cedex 1, France
| | - M Berreur
- INSERM, UMR 957, 1 rue Gaston Veil, 44035 Nantes Cedex 1, France; University of Nantes, Nantes Atlantique Universities, Laboratory of Pathophysiology of Bone Resorption and Therapy of Primary Bone Tumours, 1 rue Gaston Veil, 44035 Nantes Cedex 1, France
| | - R Brion
- INSERM, UMR 957, 1 rue Gaston Veil, 44035 Nantes Cedex 1, France; University of Nantes, Nantes Atlantique Universities, Laboratory of Pathophysiology of Bone Resorption and Therapy of Primary Bone Tumours, 1 rue Gaston Veil, 44035 Nantes Cedex 1, France; Nantes University Hospital, 1 place Alexis-Ricordeau, 44093 Nantes Cedex 1, France
| | - F Gouin
- INSERM, UMR 957, 1 rue Gaston Veil, 44035 Nantes Cedex 1, France; University of Nantes, Nantes Atlantique Universities, Laboratory of Pathophysiology of Bone Resorption and Therapy of Primary Bone Tumours, 1 rue Gaston Veil, 44035 Nantes Cedex 1, France; Nantes University Hospital, 1 place Alexis-Ricordeau, 44093 Nantes Cedex 1, France
| | - P Layrolle
- INSERM, UMR 957, 1 rue Gaston Veil, 44035 Nantes Cedex 1, France; University of Nantes, Nantes Atlantique Universities, Laboratory of Pathophysiology of Bone Resorption and Therapy of Primary Bone Tumours, 1 rue Gaston Veil, 44035 Nantes Cedex 1, France
| | - N Passuti
- INSERM, UMR 957, 1 rue Gaston Veil, 44035 Nantes Cedex 1, France; University of Nantes, Nantes Atlantique Universities, Laboratory of Pathophysiology of Bone Resorption and Therapy of Primary Bone Tumours, 1 rue Gaston Veil, 44035 Nantes Cedex 1, France; Nantes University Hospital, 1 place Alexis-Ricordeau, 44093 Nantes Cedex 1, France
| | - D Heymann
- INSERM, UMR 957, 1 rue Gaston Veil, 44035 Nantes Cedex 1, France; University of Nantes, Nantes Atlantique Universities, Laboratory of Pathophysiology of Bone Resorption and Therapy of Primary Bone Tumours, 1 rue Gaston Veil, 44035 Nantes Cedex 1, France; Nantes University Hospital, 1 place Alexis-Ricordeau, 44093 Nantes Cedex 1, France
| |
Collapse
|